US biotech Revance Therapeutics (Nasdaq: RVNC) closed trading 22% higher on Thursday.
The Nashville, Tennessee company announced that it had received approval from the US Food and Drug Administration (FDA) for Daxxify (daxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.
"Disruptive innovation to an industry that has remained largely unchanged for over 30 years"Daxxify will challenge Botox’s (botulinum toxin) long domination of the aesthetics market, and works similarly to the AbbVie (NYSE: ABBV) product in blocking chemical signals from nerves that cause muscles to contract.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze